vs
Bioceres Crop Solutions Corp.（BIOX）与SenesTech, Inc.（SNES）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是SenesTech, Inc.的184.3倍（$77.6M vs $421.0K）。Bioceres Crop Solutions Corp.净利率更高（-9.6% vs -428.5%，领先418.9%）。SenesTech, Inc.同比增速更快（-16.0% vs -16.8%）。过去两年SenesTech, Inc.的营收复合增速更高（0.7% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
SenesTech是一家农业生物技术生命科学企业，专注于通过生育调控实现害鼠防治。公司核心产品ContraPest可使褐家鼠与黑家鼠丧失生育能力，以此达到控鼠效果，公司总部位于美国亚利桑那州凤凰城。
BIOX vs SNES — 直观对比
营收规模更大
BIOX
是对方的184.3倍
$421.0K
营收增速更快
SNES
高出0.9%
-16.8%
净利率更高
BIOX
高出418.9%
-428.5%
两年增速更快
SNES
近两年复合增速
-8.4%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $421.0K |
| 净利润 | $-7.4M | $-1.8M |
| 毛利率 | 46.8% | 55.3% |
| 营业利润率 | 9.3% | -446.8% |
| 净利率 | -9.6% | -428.5% |
| 营收同比 | -16.8% | -16.0% |
| 净利润同比 | -20.2% | -43.7% |
| 每股收益（稀释后） | $-0.12 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXSNES
| Q4 25 | — | $421.0K | ||
| Q3 25 | $77.6M | $690.0K | ||
| Q2 25 | — | $625.0K | ||
| Q1 25 | $60.6M | $485.0K | ||
| Q4 24 | $98.8M | $501.0K | ||
| Q3 24 | $93.3M | $482.0K | ||
| Q2 24 | — | $459.0K | ||
| Q1 24 | $84.0M | $415.0K |
净利润BIOXSNES
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-7.4M | $-1.3M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | $-1.6M | $-1.7M | ||
| Q4 24 | $605.2K | $-1.3M | ||
| Q3 24 | $-6.2M | $-1.5M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | $9.8M | $-1.8M |
毛利率BIOXSNES
| Q4 25 | — | 55.3% | ||
| Q3 25 | 46.8% | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | 39.4% | 64.5% | ||
| Q4 24 | 42.0% | 60.9% | ||
| Q3 24 | 40.2% | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | 50.8% | 32.5% |
营业利润率BIOXSNES
| Q4 25 | — | -446.8% | ||
| Q3 25 | 9.3% | -195.2% | ||
| Q2 25 | — | -258.2% | ||
| Q1 25 | 1.5% | -342.9% | ||
| Q4 24 | 14.5% | -250.9% | ||
| Q3 24 | 2.5% | -321.0% | ||
| Q2 24 | — | -349.0% | ||
| Q1 24 | 15.7% | -444.1% |
净利率BIOXSNES
| Q4 25 | — | -428.5% | ||
| Q3 25 | -9.6% | -188.1% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | -2.6% | -343.3% | ||
| Q4 24 | 0.6% | -250.5% | ||
| Q3 24 | -6.6% | -313.9% | ||
| Q2 24 | — | -345.1% | ||
| Q1 24 | 11.6% | -441.4% |
每股收益（稀释后）BIOXSNES
| Q4 25 | — | $0.48 | ||
| Q3 25 | $-0.12 | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | $-0.02 | $-1.28 | ||
| Q4 24 | $0.00 | $-0.15 | ||
| Q3 24 | $-0.10 | $-2.07 | ||
| Q2 24 | — | $-3.08 | ||
| Q1 24 | $0.14 | $-3.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $8.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $288.3M | $9.6M |
| 总资产 | $734.9M | $12.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOXSNES
| Q4 25 | — | $8.6M | ||
| Q3 25 | $15.5M | $10.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | $38.5M | $1.7M | ||
| Q4 24 | $29.2M | $1.3M | ||
| Q3 24 | $32.3M | $2.5M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | $16.4M | $3.6M |
股东权益BIOXSNES
| Q4 25 | — | $9.6M | ||
| Q3 25 | $288.3M | $11.3M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | $345.0M | $2.9M | ||
| Q4 24 | $346.3M | $2.5M | ||
| Q3 24 | $346.0M | $3.7M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | $348.5M | $4.6M |
总资产BIOXSNES
| Q4 25 | — | $12.8M | ||
| Q3 25 | $734.9M | $14.6M | ||
| Q2 25 | — | $10.4M | ||
| Q1 25 | $798.2M | $3.6M | ||
| Q4 24 | $835.2M | $3.3M | ||
| Q3 24 | $827.3M | $4.4M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | $836.1M | $5.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-1.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.7M |
| 自由现金流率自由现金流/营收 | — | -398.3% |
| 资本支出强度资本支出/营收 | — | 3.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-5.9M |
8季度趋势，按日历期对齐
经营现金流BIOXSNES
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $14.4M | $-1.4M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | $23.3M | $-1.6M | ||
| Q4 24 | $-5.4M | $-1.2M | ||
| Q3 24 | $5.2M | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | $-17.4M | $-1.8M |
自由现金流BIOXSNES
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-1.8M |
自由现金流率BIOXSNES
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | — | -441.2% |
资本支出强度BIOXSNES
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | — | 0.5% |
现金转化率BIOXSNES
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
